secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001517022-25-000004
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akebia guides cash runway of at least two years, funding Vafseo launch and pipeline
--------------------------------------------------------------------------------

- Expects existing cash and cash from ops to fund current plan for at least two years.
- Funding supports U.S. Vafseo launch and planned pipeline advancement.
- CEO John Butler presenting at 43rd Annual J.P. Morgan Healthcare Conference on Jan 16, 2025.
- Cautionary language regarding potential need for additional funding if plan changes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000151702225000004/0001517022-25-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000151702225000004/akba-20250113.htm
  HTML page:      https://secwatch.observer/filing/0001517022-25-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer